Wolters Kluwer drops pharma business

Healthcare information provider and consultancy, Wolters Kluwer, is to divest its pharmaceutical solutions business to focus on supporting other aspects of the healthcare market.

Nancy McKinstry, CEO and chairman of the executive board of Wolters Kluwer, said: "The planned divestment of the pharma business will focus our health division on taking full advantage of our leading positions in professional information and clinical decision support solutions, one of the fastest growing areas of health, to deliver enhanced value to our stakeholders."

The company's pharmaceutical business currently includes products such as Source and Adis, with services providing support in development, marketing and distribution. This is made in available through textbooks and journals, electronic drug data, clinical information, and other evidence-based content.

The divestiture is expected to close around the end of the 2011.